{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:32Z","timestamp":1791855812901,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020219","name":"Helen and Ejnar Bj\u00f8rnow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004824","name":"Danish Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004915","name":"Nyreforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010983","name":"Region Midtjyllands Sundhedsvidenskabelige Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.02.035","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:37:14Z","timestamp":1774658234000},"page":"1308-1317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy"],"prefix":"10.1016","volume":"109","author":[{"given":"Tilde","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Tougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Daugaard","family":"Thuesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Daugaard","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Rydahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Lyngs\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Holden","family":"Mose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Bech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Maria","family":"Gramkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon W.","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Bang","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsela","family":"Resuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1016\/j.kint.2026.02.035_bib1","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.035_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.3.5720.421","article-title":"Controlled trial of prednisone in adult patients with the nephrotic syndrome","volume":"3","author":"Black","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.kint.2026.02.035_bib3","first-page":"18","article-title":"Adult minimal change nephropathy: experience of the collaborative study of glomerular disease","volume":"97","author":"Coggins","year":"1986","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.kint.2026.02.035_bib4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/bmj.291.6505.1305","article-title":"Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome","volume":"291","author":"Imbasciati","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.kint.2026.02.035_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","article-title":"The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series","volume":"69","author":"Maas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.035_bib6","article-title":"Predictors of relapse in adult-onset nephrotic minimal change disease","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2026.02.035_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000046215","article-title":"Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis","volume":"21","author":"Huang","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12882-018-0999-x","article-title":"Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes","volume":"19","author":"Fenton","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ckj\/sft063","article-title":"Minimal-change disease in adolescents and adults: epidemiology and therapeutic response","volume":"6","author":"Keskar","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.02.035_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2026.02.035_bib11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/ndt\/14.8.1889","article-title":"The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997","volume":"14","author":"Heaf","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10157-021-02119-3","article-title":"Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease","volume":"26","author":"Tanabe","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39893-x","article-title":"The influence of calcitriol and methylprednisolone on podocytes function in minimal change disease in vitro model","volume":"13","author":"Grubczak","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2026.02.035_bib14","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.3390\/ijms24043751","article-title":"Vitamin D and diabetic kidney disease","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.02.035_bib15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","article-title":"Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial","volume":"51","author":"Szeto","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.035_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","article-title":"Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial","volume":"59","author":"Liu","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.035_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","article-title":"Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial","volume":"54","author":"Fishbane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.035_bib18","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.035_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.02.035_bib45","unstructured":"Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy (ADAPTinMCN). ClinicalTrials.gov Identifier: NCT03210688. Updated January 24, 2025. Accessed April 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03210688"},{"key":"10.1016\/j.kint.2026.02.035_bib20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13063-021-05393-4","article-title":"A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN)","volume":"22","author":"Kristensen","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.kint.2026.02.035_bib21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/ndt\/gfaf072","article-title":"Temporal trends in the treatment of relapsing minimal change podocytopathy - a binational cohort study","volume":"40","author":"Kristensen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.kint.2026.02.035_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.kint.2026.02.035_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.035_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaip.2020.08.032","article-title":"Quantification of glucocorticoid-associated morbidity in severe asthma using the Glucocorticoid Toxicity Index","volume":"9","author":"McDowell","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.kint.2026.02.035_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-Item Health Survey 1.0","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ"},{"key":"10.1016\/j.kint.2026.02.035_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2026.02.035_bib28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.035_bib29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.02.035_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib46","unstructured":"Treatment of primary minimal change nephropathy. A randomized, open-labeled, non-inferiotiry study on prednisolone and vitamin D. EudraCT Number: 2017-001206-16. Updated January 21, 2025. Accessed April 13, 2026. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001206-16\/DK"},{"key":"10.1016\/j.kint.2026.02.035_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ndt\/gfp422","article-title":"Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome","volume":"25","author":"Eguchi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib32","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfx035","article-title":"Efficacy of mycophenolate treatment in adults with steroid-dependent\/frequently relapsing idiopathic nephrotic syndrome","volume":"10","author":"Sandoval","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.02.035_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s10157-014-1022-x","article-title":"Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR)","volume":"19","author":"Yokoyama","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib35","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/ndt\/11.11.2192","article-title":"Long-term outcome of adult-onset minimal-change nephropathy","volume":"11","author":"Mak","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10157-013-0793-9","article-title":"Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study","volume":"17","author":"Shinzawa","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ndt\/gfae208","article-title":"Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions in adults: a randomized controlled trial","volume":"40","author":"Chen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.035_bib39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.kint.2026.02.035_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/PNXB5040","article-title":"Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT","volume":"26","author":"Jayne","year":"2022","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.kint.2026.02.035_bib47","unstructured":"Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS). ClinicalTrials.gov Identifier: NCT00987389. Updated May 26, 2020. Accessed April 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00987389"},{"key":"10.1016\/j.kint.2026.02.035_bib41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.035_bib42","first-page":"16","article-title":"The efficacy of rituximab in adult frequently relapsing minimal change disease","volume":"10","author":"King","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.02.035_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000360908","article-title":"Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review","volume":"39","author":"Kronbichler","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.02.035_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382600236X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382600236X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:52:01Z","timestamp":1779270721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382600236X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S008525382600236X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.035","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}